Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

STAT3 dual phosphorylation site inhibitor YY201

An orally bioavailable inhibitor of signal transducer and activator of transcription 3 (STAT3), with potential antineoplastic activity. Upon oral administration, STAT3 dual phosphorylation site inhibitor YY201 targets, binds to and inhibits Tyr705 and Ser727 double-site phosphorylation of STAT3, thereby inhibiting the function of STAT3. This prevents STAT3 binding to responsive gene promoters, STAT3-mediated signaling and the expression of STAT3 target genes. This inhibits the proliferation of STAT3-overexpressing tumor cells. STAT3 regulates the transcription of genes involved in several cellular functions. STAT3 is constitutively activated in a variety of human cancers and plays a key role in neoplastic transformation, uncontrolled tumor cell proliferation, resistance to apoptosis, metastasis, immune evasion, tumor angiogenesis, epithelial-mesenchymal transition (EMT) and the Warburg effect.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:STAT3 inhibitor YY201
Code name:YY 201
YY-201
YY201
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search